Management of Cardiovascular Risk Factors
Completed
- Conditions
- Cardiovascular Risk FactorsCardiovascular Diseases
- Registration Number
- NCT00848380
- Lead Sponsor
- AstraZeneca
- Brief Summary
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1492
Inclusion Criteria
- Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period
- Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period
- Patients received during the observation time new cholesterol lowering and hypertension treatment
Exclusion Criteria
- Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia. Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the combined treatment of hypertension and hyperlipidemia in cardiovascular risk management?
How does the management of cardiovascular risk factors in NCT00848380 compare to standard-of-care approaches in terms of effectiveness and safety?
What biomarkers are associated with improved outcomes in patients undergoing simultaneous treatment for hypertension and hyperlipidemia?
What are the potential adverse events linked to concurrent hypertension and hyperlipidemia therapies, and how can they be managed?
What related compounds or combination therapies are being explored by AstraZeneca and competitors for cardiovascular disease prevention?
Trial Locations
- Locations (1)
Research Site
🇨🇭Zurich, ZH, Switzerland
Research Site🇨🇭Zurich, ZH, Switzerland